Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Feb;55(2):202-204.
doi: 10.1111/cea.14584. Epub 2024 Oct 10.

Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab

Danilo Di Bona  1 , Massimo Bilancia  2 , Claudia Crimi  3 , Michelina Daddato  2 , Alida Benfante  4 , Maria Filomena Caiaffa  5 , Cecilia Calabrese  6 , Raffaele Campisi  3 , Santi Nolasco  3 , Giovanna Elisiana Carpagnano  7 , Maria D'Amato  8 , Corrado Pelaia  9 , Girolamo Pelaia  10 , Angelantonio Maglio  11 , Nicola Scichilone  4 , Giulia Scioscia  12 , Giuseppe Spadaro  13 , Massimo Triggiani  14 , Isabella Carrieri  8 , Giuseppe Valenti  15 , Alessandro Vatrella  8 , Luigi Macchia  2 , Nunzio Crimi  3
Affiliations

Cluster Analysis Identifies Patients With Severe Eosinophilic Asthma Who Achieve Super-Response and Remission With Mepolizumab

Danilo Di Bona et al. Clin Exp Allergy. 2025 Feb.

Abstract

This study identifies two distinct subgroups of patients with severe eosinophilic asthma who respond differently to mepolizumab. Cluster analysis reveals that patients with a family history of asthma, positive skin prick tests and higher baseline lung function have better treatment outcomes, highlighting the value of personalised treatment strategies.

Keywords: T2‐high phenotype; anti‐IL5; machine learning; mepolizumab; prediction of clinical response; real‐life study; remission; super‐response.

PubMed Disclaimer